The Anti-Inflammatory Drug Leflunomide Is an Agonist of the Aryl Hydrocarbon Receptor
Open accessThe DOI matches its Crossref record; 46 of the 46 references it cites were found in a registry or an index.
Abstract
BACKGROUND: The aryl hydrocarbon receptor (AhR) is a ligand-activated transcription factor that mediates the toxicity and biological activity of dioxins and related chemicals. The AhR influences a variety of processes involved in cellular growth and differentiation, and recent studies have suggested that the AhR is a potential target for immune-mediated diseases. METHODOLOGY/PRINCIPAL FINDINGS: During a screen for molecules that activate the AhR, leflunomide, an immunomodulatory drug presently used in the clinic for the treatment of rheumatoid arthritis, was identified as an AhR agonist. We aimed to determine whether any biological activity of leflunomide could be attributed to a previously unappreciated interaction with the AhR. The currently established mechanism of action of leflunomide involves its metabolism to A771726, possibly by cytochrome P450 enzymes, followed by inhibition of de novo pyrimidine biosynthesis by A771726. Our results demonstrate that leflunomide, but not its metabolite A771726, caused nuclear translocation of AhR into the nucleus and increased expression of AhR-responsive reporter genes and endogenous AhR target genes in an AhR-dependent manner. In silico Molecular Docking studies employing AhR ligand binding domain revealed favorable binding energy for leflunomide, but not for A771726. Further, leflunomide, but not A771726, inhibited in vivo epimorphic regeneration in a zebrafish model of tissue regeneration in an AhR-dependent manner. However, suppression of lymphocyte proliferation by leflunomide or A771726 was not dependent on AhR. CONCLUSIONS: These data reveal that leflunomide, an anti-inflammatory drug, is an agonist of the AhR. Our findings link AhR activation by leflunomide to inhibition of fin regeneration in zebrafish. Identification of alternative AhR agonists is a critical step in evaluating the AhR as a therapeutic target for the treatment of immune disorders.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures

![Figure 2 Activation of the AhR target genes by leflunomide. Hepa1 and HepG2 cells were treated with vehicle (V, 0.1% DMSO), TCDD (T, 1 nM), or leflunomide (L20, 20 µM; L10, 10 µM; L1, 1 µM) for 18 hours. RNA was isolated and semi quantitative RT-PCR was performed for the AhR target genes Cytochrome P450 1A1 (CYP1A1), Cytochrome P450 1A2 (CYP1A2), UDP glucuronosyltransferase 1A1 (UGT1A1), and NAD(P)H dehydrogenase [quinone 1] (NQO1), as described in the methods section. Expression analysis of GAPDH (Glyceraldehyde-3-phosphate dehydrogenase) was performed as a control. Cycle numbers during which PCR reactions were sampled are indicated. PCR products were visualized on a 2% TAE agarose gel stained with ethidium bromide. Leflunomide activated the selected panel of AhR target genes in WT Hepa1 (A) and HepG2 cells (B).](https://figures.cochat.ai/paper-figures/7fff5724e87340e987d1582b6e09519e/the-anti-inflammatory-drug-leflunomide-is-an-agonist-of-the-aryl-hydrocarbon-figure-2.jpg)






Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“While the binding modes of TCDD and other ligands within the AHR LBD of a given species (typically that of mouse or human AHR) have been predicted by these approaches, experimental confirmation of these proposed interactions are generally lacking.”
From Comparative Analysis of Homology Models of the Ah Receptor Ligand Binding Domain: Verification of Structure–Function Predictions by Site-Directed Mutagenesis of a Nonfunctional Receptor (2013) · cites this paper as [22]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“More recently, these models have been used in molecular docking studies in an attempt to elucidate the detailed interactions of some known ligands (agonists) within the AHR LBD as well as in the virtual screening of collections of putative ligands (12,18-20,22-25).”
From Comparative Analysis of Homology Models of the Ah Receptor Ligand Binding Domain: Verification of Structure–Function Predictions by Site-Directed Mutagenesis of a Nonfunctional Receptor (2013) · cites this paper as [22]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Effective targeted gene ‘knockdown’ in zebrafish
Nasevicius, A., & Ekker, S. C. (2000) · Nature Genetics · doi:10.1038/79951 · Cited by 2,483
Control of Treg and TH17 cell differentiation by the aryl hydrocarbon receptor
Quintana, F. J., Basso, A. S., Iglesias, A. H., Korn, T., Farez, M. F., Bettelli, E., Caccamo, M., Oukka, M., & Weiner, H. L. (2008) · Nature · doi:10.1038/nature06880 · Cited by 1,865
Determination of lymphocyte division by flow cytometry
Lyons, A. B., & Parish, C. R. (1994) · Journal of Immunological Methods · doi:10.1016/0022-1759(94)90236-4 · Cited by 1,657
The aryl hydrocarbon receptor links TH17-cell-mediated autoimmunity to environmental toxins
Veldhoen, M., Hirota, K., Westendorf, A. M., Buer, J., Dumoutier, L., Renauld, J.-C., & Stockinger, B. (2008) · Nature · doi:10.1038/nature06881 · Cited by 1,634
The PAS Superfamily: Sensors of Environmental and Developmental Signals
Gu, Y.-Z., Hogenesch, J. B., & Bradfield, C. A. (2000) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.40.1.519 · Cited by 1,029
Cloning of a Factor Required for Activity of the Ah (Dioxin) Receptor
Hoffman, E. C., Reyes, H., Chu, F.-F., Sander, F., Conley, L. H., Brooks, B. A., & Hankinson, O. (1991) · Science · doi:10.1126/science.1852076 · Cited by 957
The Aryl Hydrocarbon Receptor Complex and the Control of Gene Expression
Beischlag, T. V., Morales, J. L., Hollingshead, B. D., & Perdew, G. H. (2008) · Critical Reviews™ in Eukaryotic Gene Expression · doi:10.1615/critreveukargeneexpr.v18.i3.20 · Cited by 727 · cited 16×
“Inhibition of CYP1A2 increases leflunomide-induced AhR reporter gene activity As shown in Figure 4, cytochrome P450-mediated isoxazole ring scission leading to the conversion of leflunomide to A771726 results in a loss of ability to activate the AhR.”
BackgroundInfluentialConversion of Bcl-2 from Protector to Killer by Interaction with Nuclear Orphan Receptor Nur77/TR3
Lin, B., Kolluri, S. K., Lin, F., Liu, W., Han, Y.-H., Cao, X., Dawson, M. I., Reed, J. C., & Zhang, X.-K. (2004) · Cell · doi:10.1016/s0092-8674(04)00162-x · Cited by 671
Self-citationCytochrome c Release and Apoptosis Induced by Mitochondrial Targeting of Nuclear Orphan Receptor TR3
Li, H., Kolluri, S. K., Gu, J., Dawson, M. I., Cao, X., Hobbs, P. D., Lin, B., Chen, G.-Q., Lu, J.-S., Lin, F., et al. (2000) · Science · doi:10.1126/science.289.5482.1159 · Cited by 667
Self-citationThe aryl hydrocarbon receptor: a perspective on potential roles in the immune system
Stevens, E. A., Mezrich, J. D., & Bradfield, C. A. (2009) · Immunology · doi:10.1111/j.1365-2567.2009.03054.x · Cited by 413
Cited by
Aryl hydrocarbon receptor ligands in cancer: friend and foe
Murray, I. A., Patterson, A. D., & Perdew, G. H. (2014) · Nature Reviews Cancer · doi:10.1038/nrc3846 · Cited by 883
Sykes, D. B., Kfoury, Y. S., Mercier, F. E., Wawer, M. J., Law, J. M., Haynes, M. K., Lewis, T. A., Schajnovitz, A., Jain, E., Lee, D., et al. (2016) · Cell · doi:10.1016/j.cell.2016.08.057 · Cited by 500
Christian, S., Merz, C., Evans, L., Gradl, S., Seidel, H., Friberg, A., Eheim, A., Lejeune, P., Brzezinka, K., Zimmermann, K., et al. (2019) · Leukemia · doi:10.1038/s41375-019-0461-5 · Cited by 241
Role of the aryl hydrocarbon receptor in carcinogenesis and potential as an anti-cancer drug target
Kolluri, S. K., Jin, U.-H., & Safe, S. (2017) · Archives of Toxicology · doi:10.1007/s00204-017-1981-2 · Cited by 173
Self-citationSoshilov, A. A., & Denison, M. S. (2014) · Molecular and Cellular Biology · doi:10.1128/mcb.01183-13 · Cited by 128
“4A) is an atypical AhR agonist recently shown to be an activator of zebrafish AhR1a (an AhR which does not bind TCDD) in vivo (45, 46).”
Background
Metadata
- Authors
- O'Donnell, E. F., Saili, K. S., Koch, D. C., Kopparapu, P. R., Farrer, D., Bisson, W. H., Mathew, L. K., Sengupta, S., Kerkvliet, N. I., Tanguay, R. L., & Kolluri, S. K.
- Affiliations
- Oregon State University (US)
- University of Geneva (CH)
- Corresponding author
- Kolluri, Siva Kumar
- ORCID
- Venue
- PLoS ONE
- Publisher
- Public Library of Science (PLoS)
- Published
- 2010-10-01
- Volume
- 5
- Issue
- 10
- Pages
- e13128
- ISSN
- 1932-6203 (ISSN-L)
- PMC
- PMC2948512
- OpenAlex
- W2009762618
- Cited by
- 124
- References
- 45
- Citations by year
- 2026: 5 · 2025: 5 · 2024: 6 · 2023: 12 · 2022: 14 · 2021: 7 · 2020: 9 · 2019: 14 · 2018: 7 · 2017: 9 · 2016: 5 · 2015: 8 · 2014: 7 · 2013: 6 · 2012: 6
- FWCI
- 3.62
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Locations
- PLoS ONE (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- National Science Foundation (0641409)
- U.S. Department of Defense (W81XWH)
- National Institutes of Health (1f31ca144571-01)
- National Cancer Institute (F31 CA144571, 1F31CA144571-01)
- National Institute of Environmental Health Sciences (ES-00-210, R01ES016651, P30ES000210, ES016651, P42ES016465, T32ES007060)
- Topics
- Physical Sciences › Environmental Science › Health, Toxicology and Mutagenesis › Toxic Organic Pollutants Impact
- Life Sciences › Immunology and Microbiology › Immunology › Immunotoxicology and immune responses
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmacology › Pharmacogenetics and Drug Metabolism
- Keywords
- leflunomide, aryl hydrocarbon receptor, AhR agonists, A771726, pyrimidine biosynthesis inhibition, cytochrome P450 metabolism, nuclear translocation, epimorphosis, fin regeneration, zebrafish, lymphocyte proliferation, rheumatoid arthritis, anti-inflammatory agents, immune-mediated diseases
- MeSH terms
- Leflunomide, Animals, Anti-Inflammatory Agents, Base Sequence, Cell Line, Fluorescent Antibody Technique, Isoxazoles, Ligands, Mice, Inbred C57BL, Regeneration, Zebrafish, Polymerase Chain Reaction, Genes, Reporter, DNA Primers, Receptors, Aryl Hydrocarbon, Cytochrome P-450 CYP1A2, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The Anti-Inflammatory Drug Leflunomide Is an Agonist of the Aryl Hydrocarbon Receptor. https://app.cochat.ai/papers/10.1371/journal.pone.0013128
- The paper
- O'Donnell, E. F., Saili, K. S., Koch, D. C., Kopparapu, P. R., Farrer, D., Bisson, W. H., Mathew, L. K., Sengupta, S., Kerkvliet, N. I., Tanguay, R. L., & Kolluri, S. K. (2010). The Anti-Inflammatory Drug Leflunomide Is an Agonist of the Aryl Hydrocarbon Receptor. PLoS ONE. https://doi.org/10.1371/journal.pone.0013128
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.